Chardan Capital Estimates Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Chardan Capital issued their FY2025 EPS estimates for shares of Zura Bio in a report released on Wednesday, March 26th. Chardan Capital analyst D. Gataulin forecasts that the company will earn ($0.77) per share for the year. Chardan Capital currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Chardan Capital also issued estimates for Zura Bio’s FY2026 earnings at ($0.78) EPS.

ZURA has been the topic of a number of other reports. HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Guggenheim restated a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday. Oppenheimer reaffirmed an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research note on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.00.

Zura Bio Price Performance

ZURA stock opened at $1.36 on Friday. The firm has a fifty day moving average price of $1.47 and a 200 day moving average price of $2.75. Zura Bio has a fifty-two week low of $1.07 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $0.00 million during the quarter.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Two Sigma Advisers LP purchased a new stake in Zura Bio in the 4th quarter valued at about $32,000. Shay Capital LLC purchased a new stake in shares of Zura Bio in the fourth quarter valued at approximately $233,000. ProShare Advisors LLC purchased a new position in Zura Bio during the 4th quarter worth $35,000. Millennium Management LLC raised its position in Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after purchasing an additional 657,420 shares in the last quarter. Finally, Forefront Analytics LLC lifted its holdings in shares of Zura Bio by 74.4% in the 4th quarter. Forefront Analytics LLC now owns 53,734 shares of the company’s stock worth $134,000 after buying an additional 22,924 shares during the period. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.